Text Only
Search

Head of Nairobi AIDS Orphanage Warns of Growing Resistance to Drug Treatment


06 October 2008

UNAIDS says children under the age of 15 account for one in six AIDS-related deaths around the world and one in seven new HIV infections. In some countries, AIDS is the leading cause of death for those under age five. While AIDS drugs formulated for children are available, the head of a Kenyan orphanage warns that resistance to them is growing. VOA’s Joe De Capua reports.      

Recently, at the Nyumbani orphanage in Nairobi, a 13-year-old boy named Sammy died. He was infected with HIV, the AIDS virus, and the drugs available to treat his disease no longer worked. The virus resisted all of them. To executive director Sister Mary Owens, Sammy’s death was a warning sign.

Sister_Mary_Owens_Nyumbani_160
Sister Mary Owens at Nyumbani Orphanage
"If our children develop resistance, well, first of all, we’re back to square one," she says. "And it is a fatal disease again. But also, resistance builds up in our world to the drugs. They’re ineffective. So, you just think 10 years down the line what it could be, the scenario could be."

Resistance means the drugs, known as anti-retrovirals, or ARVs, are no longer helping prevent HIV from reproducing and that the immune system is very vulnerable to opportunistic infections. Some medical

Researchers say a person can build up resistance to AIDS drugs in just two years, requiring a change in medication. But there are only so many drugs available with which to make different combinations.

Sister Mary says some of the HIV-positive children at Nyumbani are on second or even third-line drugs because they’ve built up a resistance to their initial treatment.

"I am not a scientist," she says. "I am a mother, caring for children. These are my children and I want the best for them."

Sister Mary carries on the work of Nyumbani’s founder, Father Angelo D’Agostino, a Jesuit priest, surgeon and psychiatrist, who died in late 2006 at age 80. Nyumbani cares for thousands of children through its home, village and community programs and many of those children are on anti-retrovirals.

"The children in Nyumbani home," she says, "were abandoned either because they were left on the side of the street or in a hospital after the mother delivered or at the police station or some Good Samaritan realize the parent had died and there was a sick child there. So, they’re abandoned in the strict sense. The other form of abandonment: abandonment through rejection. In other words when the parents died the extended family just disappeared."

She often blames stigma and discrimination for a family’s refusal to care for an HIV-infected child.

To help save other children from the fate of Sammy, Sister Mary says Nyumbani needs a genetic analyzer. She says it could identify which drugs would or would not be effective in treating a particular child.

"It shows up whether resistance has developed to the different ARVs," she said. "Now, it’s crucial to know if resistance is developing because that’s a warning sign about treatment failure. Ideally, before you ever go on ARVs you should have a resistance test. Because now, you see, especially in the case of our children, they can inherit a resistant virus. This virus is very clever. You know that. It mutates."

But a genetic analyzer is expensive - "Over $50,000. Would anybody like to give me a gift?" she laughs.

And each test, she says, costs about $260. Sister Mary Owens is calling on pharmaceutical companies to make a greater variety of pediatric AIDS drugs to deal with the growing drug resistance she’s seeing.

Another organization that operates many children’s AIDS programs in Africa agrees more must be done to make ARVs available. The Elizabeth Glaser Foundation says even when pediatric AIDS drugs are in good supply, it can be a challenge to make sure children get them. It says this is especially true in remote areas, where it’s difficult to diagnose infants and children with HIV, or where doctors are reluctant to treat HIV positive children because of a lack of training.

Both Nyumbani and the Glaser Foundation get much of their funding for AIDS drugs from PEPFAR, the President’s Emergency Plan for AIDS Relief. 

Focus pointer bullet Feedback

We'd like to hear what you have to say. Let us know what you think of this report and other news and features on our website. Email your views about what is happening in Africa to: africa@voanews.com. Please include your name and phone number if you would like us to include your comments on our programs. Or, telephone us and leave a message. In the US, call: (202) 205-9942. After you hear the VOA greeting, press the number "30" and leave your opinion.  We may use it on our daily broadcasts.


 

emailme.gif E-mail This Article
printerfriendly.gif Print Version

  Top Story
US Auto Companies Appeal to Congress for Help  Audio Clip Available

  More Stories
Major European Interest Rate Cuts Fail to Rally World Markets  Audio Clip Available
Rice Says Pakistan Committed to Mumbai Investigation
Israeli Soldiers Drag Jewish Settlers From House in Hebron  Audio Clip Available
Zimbabwe Declares National Cholera Emergency  Audio Clip Available
Russia Set for Immediate Response to Positive US Signals  Audio Clip Available
Bombers Strike as Iraq Gives Final Approval of US Pact
Canadian PM Shuts Down Parliament to Avoid No-Confidence Vote
Chistmas Pageantry Begins In Washington
UN Security Council Has 'Cautious Optimism' for Afghanistan's Future  Audio Clip Available
Bangkok Airport Back in Operation, But Economic Pain May Linger  Audio Clip Available
S. Korean School Isolates N. Korean Defectors to Better Integrate Them  Audio Clip Available
Measles Deaths Worldwide Fall by 74 Percent  Audio Clip Available
NASA Delays 2009 Mars Mission Due to Technical Problems  Audio Clip Available